Unlocking the Future of Medicine: Universal Protein Degradation with 3C Therapeutics.

Dan is a seasoned biotech executive with over two decades of experience in drug development, company formation, and global commercialization. He was the founding CEO of Valocor Therapeutics, the predecessor company to Dermira (NASDAQ: DERM), which Eli Lilly acquired for $1.1B. He also served as CEO of ImStar Therapeutics, an early-stage biotech company developing novel therapeutics for ALS. Earlier in his career, Dan led early commercialization efforts for Remicade® at Centocor (now part of Johnson & Johnson), a cornerstone in the development of J&J’s top-selling pharmaceutical product. He later held senior corporate development roles at QLT Inc., advancing global partnerships with Novartis, Astellas, and Sanofi. As CEO of 3C Therapeutics, Dan brings deep expertise in company building, venture financing, and strategic partnering to drive the advancement of the company’s novel DAC (Degrader-Antibody Conjugate) platform. He is also a Strategic Commercialization Advisor to Genome BC and has served on national and industry advisory boards supporting biotech innovation across Canada.

Benjamin was the first employee of 3C Therapeutics, joining after a joint research collaboration between David Perrin and iProgen, where he focused on the development and evaluation of DACs. His work successfully yielded the first prototype of an A-PROTAC through the synthesis of a degrader library. He received his PhD in organic chemistry from the Technical University Berlin in 2017, and subsequently worked at Cellbricks Inc., developing biocompatible polymers for printable 3D-Cell-Cultures and transplants. After moving to Canada, he worked as a PostDoc fellow under the supervision of Dr. Perrin, focusing on the development and evaluation of peptide toxins for Antibody-drug conjugates. His extensive experience in synthesizing, purifying, and evaluating PROTACs, A-PROTACs, and ADCs, coupled with his leadership in this project, is foundational to the advanced development of our platform.

Dr. Perrin has more than 20 years of experience in medicinal chemistry and more than 120 publications in the field. A Professor of Chemistry at UBC and a leading researcher in bio-organic chemistry, David's work bridges synthetic organic chemistry, molecular biology, physical organic chemistry, and radiochemistry to tackle long-standing challenges at the interface of chemistry and biology. His research has made significant fundamental impacts and contributed to several therapeutic applications. He was honored with the Teva and Bernard Belleau Awards of the Can. Chem. Soc. in 2015 and 2019, respectively. His discovery of one-step F-18 radiolabelling platform led to the founding of Alpha9Theranostics Inc (now Alpha-9 Oncology Inc. www.a9oncology.com), which raised $250 million to date. His collaboration with iProgen Biotech led to the development of Tri-core Degrader Antibody Conjugate platform that led to the founding of 3C Therapeutics.

Ken is a biotech entrepreneur with 25 years of experience in the field. Ken’s journey has seen him navigate through target discovery at the BC Cancer Research Center, preclinical research at Inimex Pharmaceuticals, clinical research management at BC Clinical Research, and business development roles at Helios & iProgen. He held a certification from RAPS in US Regulatory Affairs and was designated as a Clinical Research Professional by the Society of Clinical Research. Ken holds B.Sc. from UBC and MBA from the Richard Ivey School of Business.

Tony has been a leader in the biotechnology and pharmaceutical sector for more than 30 years. He currently serves on the Board of Directors for Brainstorm Cell Therapeutics, a company developing innovative therapies for the treatment of neurodegenerative diseases. He was formerly the Executive Vice President, Early Development and Chief Scientific Officer at Zymeworks Inc., where he oversaw the development of Zanidatamab, eventually out-licensed to Jazz Pharmaceuticals in a multi-billion-dollar deal. Prior to Zymeworks, Dr. Polverino served as interim Chief Scientific Officer at Kite, which Gilead acquired for $11.9B. During his tenure, Kite developed axicabtagene ciloleucel (Yescarta®), a chimeric antigen receptor (CAR-T cell immunotherapy recently approved in the United States for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Before joining Kite, Dr. Polverino spent 20 years at Amgen, holding various positions of increasing responsibility, including Director in the Oncology Department and Executive Director and Head of the Therapeutic Innovation Unit, where he led the discovery and development of multiple IND programs. Dr. Polverino earned his PhD from Flinders University and a BSc from Adelaide University.

Mike brings over 25 years of experience in the Antibody-Drug Conjugate (ADC) field, including in the chemistry, manufacturing, and controls (CMC) of clinical and commercial ADCs. He has held various leadership roles, including SVP of CMC for VelosBio (acquired by Merck for $2.75B), VP of Manufacturing at Silverback Therapeutics, and various leadership roles during his 17-year tenure at Seagen. Mike has participated in the development and submission of more than 30 antibody and ADC INDs and 4 BLAs, including serving as the CMC Lead of commercial ADCs ADCETRIS and PADCEV. Mike currently serves as technical advisor to multiple biotechnology companies developing ADCs. His extensive expertise in ADCs is indispensable for our DAC (Degrader-Antibody Conjugate) platform's advancement, including its inherent advantages for efficient and scalable manufacturing.